title: Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis.
abstract: OBJECTIVE
  To determine the main clinical and genetic factors having impact on early coronary stent thrombosis.
  
  
  METHODS
  Genotyping of CYP2C19*2, *17 and CYP4F2*3 in patients with (n = 31) and without stent thrombosis (n = 456) was performed. Clinical and genetic data were analyzed by binary logistic regression.
  
  
  RESULTS
  Smoking (OR: 0.317; 95% CI: 0.131-0.767), high-density lipoprotein level in mmol/l (OR: 0.142; 95% CI: 0.040-0.506), CYP2C19*2*2 versus *1*1 and *1*2 genotype (OR: 11.625; 95% CI: 3.498-38.633), CYP4F2 AA versus GA and GG genotype (OR: 3.532; 95% CI: 1.153-10.822) were associated with early stent thrombosis.
  
  
  CONCLUSIONS
  For the first time we have identified a clinically important polymorphism (CYP4F2 G1347A) that was independently associated with early stent thrombosis. Original submitted 18 August 2014; Revision submitted 10 November 2014.
authors.affiliation: Institute of Cardiology of Lithuanian University of Health Sciences, Sukileliu 17, Kaunas, LT 50009, Lithuania.
authors.forename: Nora
authors.initials: N
authors.lastname: Kupstyte
authors.forename: Remigijus
authors.initials: R
authors.lastname: Zaliunas
authors.forename: Vacis
authors.initials: V
authors.lastname: Tatarunas
authors.forename: Vilius
authors.initials: V
authors.lastname: Skipskis
authors.forename: Diana
authors.initials: D
authors.lastname: Zaliaduonyte-Peksiene
authors.forename: Ingrida
authors.initials: I
authors.lastname: Grabauskyte
authors.forename: Dovile
authors.initials: D
authors.lastname: Dovidaitiene
authors.forename: Karolis
authors.initials: K
authors.lastname: Bumblauskas
authors.forename: Olivija
authors.initials: O
authors.lastname: Gustiene
authors.forename: Vaiva
authors.initials: V
authors.lastname: Lesauskaite
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage; D016022:Case-Control Studies; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D000072470:Cytochrome P450 Family 4; D005260:Female; D005838:Genotype; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D008957:Models, Genetic; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011110:Polymorphism, Genetic; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects*; D013927:Thrombosis / Q000201:enzymology / Q000209:etiology* / Q000235:genetics*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D010975:Platelet Aggregation Inhibitors; D003577:Cytochrome P-450 Enzyme System; D000077144:Clopidogrel; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D000072470:Cytochrome P450 Family 4; C117480:CYP4F2 protein, human; D013988:Ticlopidine; D001241:Aspirin
keywords: cardiovascular disease; molecular biology; pharmacogenetics; polymerase chain reaction; stent; thrombosis